Clinical Trial Details
Braintumor Website

[Information provided by: ClinicalTrials.gov, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT03573986 : Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment
PhasePhase 1
AgesMin: 18 Years Max: N/A
Eligibility
Inclusion Criteria:

- Participants will be = 18 years of age

- Biopsy proven glioblastoma

- Must meet one of the following criteria:

- Recent surgery (within 2 months) showing recurrent glioblastoma with measurable (20 mm
in 2 dimensions) residual tumor.

Radiologic evidence of recurrent tumor based on conventional and advanced MRI findings.

- Recommended for clinically indicated bevacizumab therapy

- Life expectancy of greater than 3 months in the opinion of an investigator or treating
physician.

- Karnofsky performance status = 60

- Participants must be informed of the investigational nature of this study and be
willing to provide written informed consent and participate in this study in
accordance with institutional and federal guidelines prior to study-specific
procedures.

Exclusion Criteria:

- Inability to tolerate imaging procedures in the opinion of an investigator or treating
physician

- Females who are pregnant or breast feeding at the time of screening will not be
eligible for this study; a urine pregnancy test will be performed in women of
child-bearing potential at screening.

- Any current medical condition, illness, or disorder as assessed by medical record
review and/or self-reported that is considered by a physician investigator to be a
condition that could compromise participant safety or successful participation in the
study

- Less than 3 months from finishing the most recent radiation or immunotherapy.

- Contraindications to MRI or use of gadolinium contrast

- Only individuals (aged 18 or over) who can understand and give informed consent will
be approached to participate in this study. Individuals who are considered to be
mentally disabled will not be recruited for this study. All subjects must understand
and be able to give informed consent. We will not be using specific methods to assess
decisional capacity. Economically disadvantaged persons will not be vulnerable to
undue influence, as this study offers no compensation. All individuals will be told
that their choice regarding study participation will in no way change their access to
clinical care. This should negate any undue influence or coercion. Pregnant women,
children, fetuses, neonates, or prisoners are not included in this research study.
LinksPermanent Link to THIS page: https://virtualtrials.com/nct/display1trial.cfm?nct=NCT03573986      |      Link to official Clinicaltrials.gov listing
Locations



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2019 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740